Merck & Co., Inc. (LON:0QAH)

London flag London · Delayed Price · Currency is GBP · Price in USD
104.83
-0.45 (-0.43%)
At close: Nov 28, 2025
4.62%
Market Cap196.56B
Revenue (ttm)47.79B
Net Income (ttm)14.16B
Shares Outn/a
EPS (ttm)5.62
PE Ratio13.88
Forward PE11.62
Dividend2.45 (2.34%)
Ex-Dividend DateSep 15, 2025
Volume26,560
Average Volume36,667
Open104.55
Previous Close105.28
Day's Range104.00 - 105.40
52-Week Range70.15 - 106.06
Beta0.32
RSI79.51
Earnings DateFeb 3, 2026

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]

Sector Healthcare
Founded 1891
Employees 75,000
Stock Exchange London Stock Exchange
Ticker Symbol 0QAH
Full Company Profile

Financial Performance

In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.

Financial numbers in USD Financial Statements

News

There is no news available yet.